Equity Capital Markets

CytomX Therapeutics Inc.

05/25
|
$100.0 Million
cytomx
Piper Sandler served as bookrunner for CytomX Therapeutics Inc. on its RD
Sub-Type
Registered Direct
Sector
Healthcare
Sub-Sector
Biopharma

Related Transactions

All Transactions
$75.0 Million
w
Protara Therapeutics
Confidentially Marketed Follow-On Offering
Active Bookrunner
$172.5 Million
e
Capricor Therapeutics
Confidentially Marketed Follow-On Offering
Left Bookrunner
$158.7 Million
s
Kestra Medical Technologies
Follow-On Offering
Active Bookrunner
$300.0 Million
s
Compeer Financial
Perpetual Preferred Stock
Sole Initial Purchaser
4
American Integrity Insurance Group
Follow-On Offering
Active Bookrunner
$373.0 Million
z
Central Bancompany
Initial Public Offering
Joint Bookrunner
$40.2 Million
s
Fennec Pharmaceuticals
Confidentially Marketed Follow-On Offering
Lead Bookrunner
g
MultiPlan, Inc.
Confidentially Marketed Follow-On Offering
Passive Bookrunner
$110.0 Million
3
Nektar Therapeutics
ATM Program Common Stock
Lead Sales Agent
$172.5 Million
p
Inventiva Pharma
Confidentially Marketed Follow-On Offering
Active Bookrunner
$28.8 Million
e
Inovio Pharmaceuticals
Confidentially Marketed Follow-On Offering
Sole Manager
$314.0 Million
f
BillionToOne
Initial Public Offering
Active Bookrunner
$40.0 Million
r
Colony Bank
ATM Program Common Stock
Sole Sales Agent
$130.0 Million
h
Savara
Confidentially Marketed Follow-On Offering
Active Bookrunner
u
Tamboran Resources
Confidentially Marketed Follow-On Offering
Co-Manager
$10.0 Million
d
Decatur Bancshares
Subordinated Notes
Sole Placement Agent

© 2025 Piper Sandler Companies. Since 1895. All rights reserved.